Developing adaptive techniques and strategies to get around apparent disabilities (e.g., keyboarding or using a weighted pencil to facilitate handwriting)
Nausea during the first weeks of semaglutide use is one of the top reasons people discontinue the medication before seeing meaningful results
According to the Summary of Product Characteristics (SmPC), these include: Nausea (very common: may affect more than 1 in 10 people) Diarrhoea and constipation (very common) Vomiting and abdominal pain (very common) Decreased appetite and dyspepsia (very common) Most gastrointestinal adverse effects are mild to moderate in severity and tend to diminish over time as the body adjusts to treatment
Strength training and multi-joint exercises help stimulate the production of proteins
Both of these medications are GLP-1/GIP receptor agonists, which are commonly grouped with GLP-1 receptor agonists like Ozempic, even though they differ in one key way
FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight, U.S